ArticleTherapeutic advances in chronic disease2012
Indacaterol in chronic obstructive pulmonary disease: an update for clinicians.
Article in Therapeutic advances in chronic disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 11 citations in OpenAlex.
- Chronic stimulation desensitizes β2-adrenergic receptor responses in natural killer cells.European journal of immunology · 2024Article
- Real-world Safety and Efficacy of Indacaterol Maleate in Patients with Chronic Obstructive Pulmonary Disease: Evidence from the Long-term Post-marketing Surveillance in Japan.Internal medicine (Tokyo, Japan) · 2021Article
- Indacaterol inhibits tumor cell invasiveness and MMP-9 expression by suppressing IKK/NF-κB activation.Molecules and cells · 2014Article
- Indacaterol: a comprehensive review.International journal of chronic obstructive pulmonary disease · 2013Review
- Can the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?Drug design, development and therapy · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchodilation is the cornerstone of chronic obstructive pulmonary disease (COPD) management and is based on regular treatment with one or more long-acting β(2) agonists (LABAs). A novel bronchodilator, indacaterol, satisfies the requirements of an efficacious LABA: it has a relatively longer duration of action compared with existing LABAs and a fast onset of action. This review is a presentation of data on indacaterol with respect to its molecular characteristics as well as comparisons with other long-acting bronchodilators. Data from 12 relevant trials show that once-daily indacaterol provides significant, consistent and clinically important improvements in lung function (forced expiratory volume in 1 second), significant improvements in breathlessness and health status at least as good as or better than tiotropium, salmeterol and formoterol, and reduction in requirement for relief medication compared with tiotropium, salmeterol and formoterol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.